Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy.

Bone marrow transplantation·2026

Same author

Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes.

Transplantation and cellular therapy·2026

Same author

Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.

Haematologica·2026

Same author

Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant.

American journal of hematology·2026

Same author

Uncoupling toxicity from efficacy in donor selection for allogeneic hematopoietic cell transplantation: a retrospective cohort study using double machine learning.

Journal of hematology & oncology·2026

Same author

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.

Blood cancer journal·2026

Search research articles

Related Experiment Video

Updated: May 29, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Allogeneic stem cell transplantation in first complete remission.

Betul Oran¹, Daniel J Weisdorf

¹Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, Minnesota, USA. oranx002@umn.edu

Current Opinion in Hematology

|September 14, 2011

Summary

Optimal therapy for acute myeloid leukemia (AML) in first complete remission (CR1) remains unclear. Advances in risk stratification and allogeneic hematopoietic stem cell transplantation (allo-HCT) suggest early donor identification is crucial for eligible AML patients in CR1.

More Related Videos

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Related Experiment Videos

Last Updated: May 29, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Area of Science:

Hematology
Oncology
Transplantation Medicine

Background:

The optimal postremission therapy for acute myeloid leukemia (AML) in first complete remission (CR1) is not definitively established.
This review focuses on recent clinical research and therapeutic applications of allogeneic hematopoietic stem cell transplantation (allo-HCT) in CR1.

Purpose of the Study:

To review recent developments in clinical research and therapeutic applications of allo-HCT in CR1 for AML.
To define the evolving role of allo-HCT in the management of AML patients in CR1.

Main Methods:

Literature review of recent clinical research and therapeutic advancements.
Analysis of the impact of improved risk stratification and transplant technologies.

Main Results:

Improved risk stratification using molecular markers and cytogenetics enhances decision-making for AML patients in CR1.
Advances in supportive care, transplant technology, donor availability, and reduced-intensity conditioning have improved allo-HCT safety and accessibility.

Conclusions:

Progress in risk stratification and transplant technology supports early donor identification for all eligible AML patients in CR1.
The findings emphasize the growing importance of allo-HCT as a therapeutic option for AML in CR1.